Christopher Nixon Cox - Feb 1, 2024 Form 4 Insider Report for Alto Neuroscience, Inc. (ANRO)

Role
Director
Signature
/s/ Erin R. McQuade, Attorney-in-Fact
Stock symbol
ANRO
Transactions as of
Feb 1, 2024
Transactions value $
$54,940
Form type
4
Date filed
2/5/2024, 04:42 PM
Next filing
Feb 7, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANRO Stock Option (right to buy) Award $0 +30.6K $0.00 30.6K Feb 1, 2024 Common Stock 30.6K $16.00 Direct F1
transaction ANRO Stock Option (right to buy) Award $54.9K +4.62K $11.88* 4.62K Feb 1, 2024 Common Stock 4.62K $16.00 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the option shall vest in 36 equal monthly installments commencing on March 1, 2024, subject to the Reporting Person's continuous service through each vesting date.
F2 840 shares underlying the option shall vest on March 31, 2024, and 1,261 shares underlying the option shall vest on each of June 30, 2024, September 30, 2024 and December 31, 2024, subject to the Reporting Person's continuous service through each such vesting date.
F3 This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $55,000.